Women's Cancer Research Foundation
Common Analgesics and Ovarian Cancer Survival: The Ovarian Cancer Prognosis and Lifestyle
Ovarian cancer (OC) is a silent killer that often goes undetected until it reaches advanced stages.
top of page
The Way Forward Is Clearer, Together.
The Women’s Cancer Research Foundation (WCRF) annually publishes and funds numerous clinical studies on breast and gynecologic (ovarian, endometrial, and cervical) cancers. The WCRF’s oncology experts work tirelessly with the belief that each new clinical study has the potential to fundamentally improve the outcomes of patients diagnosed with breast and gynecologic cancers.
Search
Women's Cancer Research Foundation
Feb 17, 20232 min read
Incomplete Cisplatin Regimens in Chemoradiation & Effect On Outcomes for Advanced Cervical Cancer
Presumably, fewer chemotherapy cycles should adversely impact patient prognosis, and this question was addressed in a recent article in....
Women's Cancer Research Foundation
Oct 11, 20221 min read
New Treatment Brings Remission of Rectal Cancer in All Patients
A small study delivers startling results on the power of a new immunotherapy treatment against rectal cancer...
Women's Cancer Research Foundation
Jun 24, 20222 min read
Impact of Care by Gynecologic Oncologists on Primary Ovarian Cancer Survival: Population-based Study
Prompt treatment of advanced-stage ovarian cancer by a gynecologic oncologist with a combination of surgery and chemotherapy is approved...
Women's Cancer Research Foundation
May 16, 20222 min read
When Ovarian Cancer Returns, Surgery May Be a Good Choice for Selected Patients
A recent clinical trial revealed that a secondary surgery followed by chemotherapy can improve survival compared to chemotherapy alone.
Women's Cancer Research Foundation
Apr 25, 20222 min read
New Drug Combination Shown to be Effective for Patients with Advanced Ovarian Cancer
Ovarian cancer is the most lethal gynecologic malignancy. Novel approaches for relapsed ovarian cancer are necessary to improve survival.
Women's Cancer Research Foundation
Mar 22, 20221 min read
A Novel Treatment For Platinum-Resistant Ovarian Cancer
Every year in the U.S., 22,000 to 24,000 women are diagnosed with ovarian cancer. Patient survival depends upon the responses to...
Women's Cancer Research Foundation
Mar 16, 20221 min read
Racial Disparities in Non-Recommendation of Adjuvant Chemotherapy in Ovarian Cancer
In a recent study from Gynecologic Oncology, the authors identified ovarian cancer patients who underwent primary surgery from 2004 to 2015.
Women's Cancer Research Foundation
Mar 10, 20221 min read
Overall Survival and Neoadjuvant Chemotherapy in Patients With Advanced Ovarian Cancer
In a recent JAMA study, researchers endeavored to determine if there were differences in overall survival among ovarian cancer patients...
Women's Cancer Research Foundation
Dec 23, 20212 min read
Chemo Brain Is Real
“Chemo brain” refers to thinking that is sluggish or fuzzy. Essentially, this condition can interfere with executive functioning...
Women's Cancer Research Foundation
Nov 24, 20211 min read
Clinical Complications of Chemotherapy and Patient-Reported Outcomes After Breast Reconstruction
In a 2021 study, 1881 patients who received either implant-based or autologous breast reconstruction following neoadjuvant or adjuvant...
Women's Cancer Research Foundation
Oct 12, 20211 min read
Risk of Late-Onset Breast Cancer in Genetically Predisposed Women
Germline mutations in breast cancer predispose women to develop this malignancy, but in woman 65+years, the risk is not well-defined.
Women's Cancer Research Foundation
Oct 8, 20211 min read
Combination Strategies Reshape Treatment Paradigm for Advanced Endometrial Cancer
Initially, pembrolizumab was approved as a monotherapy for patients with microsatellite instability-high recurrent endometrial cancer.
Women's Cancer Research Foundation
Sep 15, 20212 min read
Cognitive Function After Cancer and Cancer Treatment
Despite these advancements, the delayed effects from chemotherapy have become progressively concerning to patients.
Women's Cancer Research Foundation
Jul 5, 20211 min read
Appropriateness of Specific Chemotherapy Regimens in Elderly Patients Diagnosed with Ovarian Cancer
Efficacy and safety of first-line single-agent carboplatin vs carboplatin plus paclitaxel for vulnerable older adult women with ovarian....
Women's Cancer Research Foundation
Apr 29, 20212 min read
Secondary cytoreduction followed by chemotherapy vs chemotherapy alone
Secondary cytoreduction followed by chemotherapy vs chemotherapy alone in platinum-sensitive relapsed ovarian cancer
bottom of page